Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Treating highly relapsed/refractory CLL

Michael Hallek • 27 Aug 2020
SOHO 2020
Chronic Lymphocytic Leukemia Leukemia Antibodies CAR-T Idelalisib Venetoclax

Michael Hallek, MD, of the University Hospital of Cologne, Cologne, Germany, outlines treatment options for relapsed/refractory patients with chronic lymphocytic leukemia and highlights the potential benefit of CAR T-cell therapies for these patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michael Hallek

2:24
BCL-2 frontline therapy in CLL
Michael Hallek • 25 Aug 2020
3:53
Updates from the German CLL Study Group
Michael Hallek • 28 Aug 2020
2:32
Value of MRD measurement in CLL
Michael Hallek • 27 Aug 2020
1:17
CLL14: venetoclax-obinutuzumab improves PFS and MRD in untreated, reduced fitness CLL
Michael Hallek • 19 Jun 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals